<DOC>
	<DOCNO>NCT00509990</DOCNO>
	<brief_summary>An open-label , multicenter study , long term management evaluate effectiveness , tolerability safety pimecrolimus cream 1 % pediatric patient mild moderate atopic dermatitis daily practice</brief_summary>
	<brief_title>Open Label Study Long Term Treatment Pediatric Treatment Atopic Dermatitis With Pimecrolimus Cream 1 % Within Usual Clinical Setting</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Age ≥ 3 month 12 year old Clinical diagnosis atopic dermatitis History mild moderate atopic dermatitis Investigator Global Assessment ≥ 1 ( almost clear/clear disease ) Written informed consent Investigator Global Assessment ≥ 4 ( severe/very severe disease ) Patients active skin viral infection ( i.e , herpes simplex , herpes zoster , varicella ) Patients atopic dermatitis , active clinical infection area disease . All active infection must treat prior trial inclusion Patients Immunosuppressive state history malignant disease Patients clinical condition Atopic Dermatitis accord investigator may interfere evaluation ( i.e , Psoriasis , Netherton Syndrome ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Atopic dermatitis , pimecrolimus , child</keyword>
</DOC>